BCL2 and acute myeloid leukemia: Further, combining these therapeutics was shown to overcome resistance to either drug alone, with p53 activation promoting MCL-1 degradation and BCL-2 inhibition shifting the p53 activation response from G1 cell cycle arrest to apoptosis, resulting in prolonged survival in murine xenograft models of resistant AML (46).